Three years ago A.P. Pharma received a complete response letter (CRL) from the FDA saying problems with manufacturing were one of the reasons the agency was not prepared to approve its lead product.
Three years after the FDA handed out its first rejection of A.P. Pharma's anti-nausea therapy APF530, regulators did it again, still unsatisfied by the biotech's marketing application. But this time the company insisted right off the bat that it can regroup, get back to the FDA and launch this therapy after about a 6-month delay in its schedule.
With its lead drug program under a dark cloud at the FDA and officials at Nasdaq frowning at its battered share price, A.P. Pharma stated today that it is "taking additional actions" to cut costs as
A.P. Pharma's shares went into a tailspin this morning after the FDA rejected the company's anti-nausea drug, a long-acting formulation of granisetron for chemo-induced vomiting. And the company was
Still trying to preserve cash, A.P. Pharma announced that it is once again cutting about a third of its staff. Back in November, the Redwood City, CA-based developer axed a third of its workforce, or
A.P. Pharma has joined the list of biotech companies cutting back in the face of the economic crisis. The developer says it has eliminated 18 positions, about a third of its workforce, and placed
A.P. Pharma says its experimental therapy to prevent nausea and vomiting induced by chemotherapy hit the primary endpoint in three of four assessments outlined in a Phase III comparison trial with